Informacja

Drogi użytkowniku, aplikacja do prawidłowego działania wymaga obsługi JavaScript. Proszę włącz obsługę JavaScript w Twojej przeglądarce.

Tytuł pozycji:

Preventing mother to child transmission of HIV: lessons learned from China.

Tytuł:
Preventing mother to child transmission of HIV: lessons learned from China.
Autorzy:
Dong Y; Department of Geriatrics, Zhongnan Hospital of Wuhan University, Wuhan, China.
Guo W; Department of Pathology, Wuhan University School of Basic Medical Sciences, Wuhan, China.; Department of Pathology, Zhongnan Hospital of Wuhan University, Wuhan, China.
Gui X; Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, China.
Liu Y; Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, China.
Yan Y; Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, China.
Feng L; Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, China.
Liang K; Department of Infectious Diseases, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, China. .; Center of Preventing Mother-to-child transmission for Infectious Diseases, Zhongnan Hospital of Wuhan University, 169 Donghu Road, Wuhan, 430071, China. .; Department of Nosocomial Infection Management, Zhongnan Hospital of Wuhan University, Wuhan University, Wuhan, Hubei, China. .
Źródło:
BMC infectious diseases [BMC Infect Dis] 2020 Oct 26; Vol. 20 (1), pp. 792. Date of Electronic Publication: 2020 Oct 26.
Typ publikacji:
Journal Article
Język:
English
Imprint Name(s):
Original Publication: London : BioMed Central, [2001-
MeSH Terms:
Anti-HIV Agents/*therapeutic use
HIV Infections/*drug therapy
HIV Infections/*epidemiology
Infectious Disease Transmission, Vertical/*prevention & control
Pre-Exposure Prophylaxis/*methods
Pregnancy Complications, Infectious/*drug therapy
Pregnancy Complications, Infectious/*epidemiology
Zidovudine/*therapeutic use
Adolescent ; Adult ; CD4 Lymphocyte Count ; China/epidemiology ; Female ; Follow-Up Studies ; HIV Infections/virology ; Humans ; Infant ; Infant, Newborn ; Middle Aged ; Pregnancy ; Pregnancy Complications, Infectious/virology ; Risk Factors ; Young Adult
References:
AIDS. 2014 Apr 24;28(7):1049-57. (PMID: 24566097)
J Acquir Immune Defic Syndr. 2002 Apr 15;29(5):484-94. (PMID: 11981365)
Curr HIV Res. 2003 Oct;1(4):447-62. (PMID: 15049430)
J Acquir Immune Defic Syndr. 2011 Feb 1;56(2):131-8. (PMID: 21124227)
Bull World Health Organ. 2017 Aug 1;95(8):574-583. (PMID: 28804169)
Clin Infect Dis. 2017 Feb 15;64(4):527-528. (PMID: 28174911)
Clin Infect Dis. 2018 May 17;66(11):1668-1677. (PMID: 29272387)
JAMA. 2000 Mar 1;283(9):1167-74. (PMID: 10703779)
Obstet Gynecol. 2010 Jun;115(6):1247-55. (PMID: 20502297)
Clin Infect Dis. 2005 Feb 1;40(3):458-65. (PMID: 15668871)
Lancet. 2016 Feb 6;387(10018):566-573. (PMID: 26603917)
J Infect Dis. 2009 Sep 1;200(5):682-6. (PMID: 19627245)
J Acquir Immune Defic Syndr. 2018 Sep 1;79(1):e17-e20. (PMID: 29781882)
Sci Rep. 2018 Dec 24;8(1):18071. (PMID: 30584264)
AIDS. 2017 Jul 17;31(11):1579-1591. (PMID: 28481770)
Lancet. 2016 Jun 18;387(10037):2488-9. (PMID: 27291996)
J Acquir Immune Defic Syndr. 2010 Feb;53 Suppl 1:S15-22. (PMID: 20104104)
Grant Information:
81000758 National Natural Science Foundation of China; PTXM2020008 Medical Science and Technology Innovation Platform Support Project of Zhongnan Hospital, Wuhan University; cxpy2017043 Science and Technology Innovation Cultivation Fund of Zhongnan Hospital, Wuhan University; PMTCT2017-005, PMTCT201901 the AbbVie foundation for maternity and child care and Prevention of mother-to-child transmission of HIV·Chinese Association of STD and AIDS Prevention and Control
Contributed Indexing:
Keywords: Antiretrovirals; HIV; Mother-to-child transmission; Prevention; Trend
Substance Nomenclature:
0 (Anti-HIV Agents)
4B9XT59T7S (Zidovudine)
Entry Date(s):
Date Created: 20201027 Date Completed: 20201106 Latest Revision: 20201106
Update Code:
20240105
PubMed Central ID:
PMC7586644
DOI:
10.1186/s12879-020-05516-3
PMID:
33106179
Czasopismo naukowe
Background: The program for the prevention of mother-to-child transmission (PMTCT) of human immunodeficiency virus (HIV) was launched in 2003 in China, but few studies have been conducted to describe the panorama of PMTCT. We investigated the rate and associated factors of mother-to-child transmission (MTCT) in China from 2004 to 2018.
Methods: HIV-infected pregnant women from two areas in China between 2004 and 2018 were enrolled. Antiretrovirals (ARVs) were provided to the mothers and their babies, and the children were followed and tested for HIV.
Results: In total, 857 mothers and their 899 children were enrolled, and the overall MTCT rate was 6.6% (95% CI 5.0-8.2). The MTCT rates of nonintervention, only formula feeding (FF), infant prophylaxis (IP) + FF, single dosage antiretrovirals (sdARVs) + IP + FF, zidovudine (AZT) alone+IP + FF and prenatal combination antiretroviral therapy (cART) + IP + FF were 36.4, 9.4, 10.0, 5.7, 3.8 and 0.3%, respectively. The MTCT rate declined over time. No ARVs, CD4 count < 200/μL, low birth weight, and breastfeeding were associated with MTCT of HIV. For different ARVs, a higher MTCT rate was observed for AZT alone, sdARVs, and no ARVs compared to cART for pregnant women.
Conclusions: Although the overall MTCT rate remains relatively high, the real-world effect of prenatal cART+IP + FF in China has exerted the same protective effects in high-income countries. With the extension of prenatal cART for pregnant women with HIV, the MTCT rate of HIV has gradually declined in China. However, the coverage of prenatal cART for pregnant women should be further improved. The effect of only post-exposure prophylaxis for infants was limited.
Zaloguj się, aby uzyskać dostęp do pełnego tekstu.

Ta witryna wykorzystuje pliki cookies do przechowywania informacji na Twoim komputerze. Pliki cookies stosujemy w celu świadczenia usług na najwyższym poziomie, w tym w sposób dostosowany do indywidualnych potrzeb. Korzystanie z witryny bez zmiany ustawień dotyczących cookies oznacza, że będą one zamieszczane w Twoim komputerze. W każdym momencie możesz dokonać zmiany ustawień dotyczących cookies